Praveen Neeli

774 total citations · 1 hit paper
23 papers, 541 citations indexed

About

Praveen Neeli is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Praveen Neeli has authored 23 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Immunology. Recurrent topics in Praveen Neeli's work include Immunotherapy and Immune Responses (6 papers), RNA Interference and Gene Delivery (5 papers) and Cancer Mechanisms and Therapy (4 papers). Praveen Neeli is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), RNA Interference and Gene Delivery (5 papers) and Cancer Mechanisms and Therapy (4 papers). Praveen Neeli collaborates with scholars based in United States, India and China. Praveen Neeli's co-authors include Srigiridhar Kotamraju, Santosh Karnewar, Navid Sobhani, Dafei Chai, Mahesh Kumar Jerald, Nishant Jain, K. Sasikumar, Paradesi Naidu Gollavilli, Yong Li and Giandomenico Roviello and has published in prestigious journals such as Oncogene, Chemical Communications and International Journal of Molecular Sciences.

In The Last Decade

Praveen Neeli

23 papers receiving 536 citations

Hit Papers

The next-generation DNA vaccine platforms and delivery sy... 2024 2026 2025 2024 20 40 60

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Praveen Neeli United States 11 294 141 127 77 68 23 541
Bing Wei China 19 256 0.9× 134 1.0× 103 0.8× 107 1.4× 41 0.6× 42 755
Yueshuang Ke China 13 382 1.3× 115 0.8× 267 2.1× 53 0.7× 35 0.5× 19 609
Ruxian Lin United States 16 407 1.4× 62 0.4× 91 0.7× 118 1.5× 38 0.6× 40 722
David Gagné Canada 11 264 0.9× 56 0.4× 154 1.2× 59 0.8× 122 1.8× 18 739
Yuejie Xu China 11 278 0.9× 122 0.9× 123 1.0× 89 1.2× 50 0.7× 17 529
Lydia Brandl Germany 11 371 1.3× 45 0.3× 220 1.7× 81 1.1× 110 1.6× 20 626
Meredith S. Carson United States 11 265 0.9× 101 0.7× 114 0.9× 69 0.9× 154 2.3× 15 556
Anthony Andren United States 9 344 1.2× 93 0.7× 100 0.8× 159 2.1× 42 0.6× 14 537
Qiaoli Zheng China 12 267 0.9× 88 0.6× 85 0.7× 117 1.5× 23 0.3× 30 627
Travis Lear United States 17 476 1.6× 215 1.5× 81 0.6× 64 0.8× 51 0.8× 29 722

Countries citing papers authored by Praveen Neeli

Since Specialization
Citations

This map shows the geographic impact of Praveen Neeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Praveen Neeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Praveen Neeli more than expected).

Fields of papers citing papers by Praveen Neeli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Praveen Neeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Praveen Neeli. The network helps show where Praveen Neeli may publish in the future.

Co-authorship network of co-authors of Praveen Neeli

This figure shows the co-authorship network connecting the top 25 collaborators of Praveen Neeli. A scholar is included among the top collaborators of Praveen Neeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Praveen Neeli. Praveen Neeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sahoo, Sashikanta, et al.. (2025). MTDH∆7-mediated mTOR activation drives doxorubicin resistance in triple-negative breast cancer: Relevance of mTORC1 inhibition on chemosensitization. Cellular Signalling. 132. 111864–111864. 2 indexed citations
2.
Lu, Bowen, Siyuan Song, Praveen Neeli, et al.. (2024). The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Frontiers in Immunology. 15. 1332939–1332939. 69 indexed citations breakdown →
3.
Chai, Dafei, Junhao Wang, Chunmei Fan, et al.. (2024). Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. Journal of Hematology & Oncology. 17(1). 45–45. 9 indexed citations
4.
Neeli, Praveen, Dafei Chai, Dan Zhao, et al.. (2024). DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma. npj Vaccines. 9(1). 4 indexed citations
5.
Ding, Jiage, Fei Zhu, Navid Sobhani, et al.. (2023). The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma. npj Vaccines. 8(1). 109–109. 5 indexed citations
6.
Chai, Dafei, et al.. (2023). DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice. Genes & Diseases. 11(4). 100994–100994. 2 indexed citations
7.
Neeli, Praveen, Dafei Chai, Xu Wang, et al.. (2023). Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2. iScience. 26(7). 107120–107120. 8 indexed citations
8.
Shi, Xiaoqing, Jiage Ding, Jiawei Wang, et al.. (2023). HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma. iScience. 26(3). 106143–106143. 12 indexed citations
9.
Zhou, Shan, Dafei Chai, Xu Wang, et al.. (2023). AI-powered discovery of a novel p53-Y220C reactivator. Frontiers in Oncology. 13. 1229696–1229696. 9 indexed citations
10.
Neeli, Praveen, et al.. (2022). DOT1L regulates MTDH ‐mediated angiogenesis in triple‐negative breast cancer: intermediacy of NF‐κB‐HIF1α axis. FEBS Journal. 290(2). 502–520. 16 indexed citations
11.
Sobhani, Navid, Bruna Scaggiante, Dafei Chai, et al.. (2022). Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. Cancer Treatment Reviews. 109. 102429–102429. 58 indexed citations
13.
Chai, Dafei, et al.. (2022). C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response. Frontiers in Physiology. 13. 1012112–1012112. 5 indexed citations
14.
Sobhani, Navid, Praveen Neeli, Alberto D’Angelo, et al.. (2021). AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. International Journal of Molecular Sciences. 22(11). 5515–5515. 39 indexed citations
15.
Neeli, Praveen, Rintu Banerjee‬‬‬‬‬‬‬‬‬, Maddi Sridhar Reddy, et al.. (2021). A functional and self-assembling octyl-phosphonium-tagged esculetin as an effective siRNA delivery agent. Chemical Communications. 57(92). 12329–12332. 6 indexed citations
16.
Neeli, Praveen, et al.. (2020). sp3‐Rich Glycyrrhetinic Acid Analogues Using Late‐Stage Functionalization as Potential Breast Tumor Regressing Agents. ChemMedChem. 15(19). 1826–1833. 6 indexed citations
19.
Karnewar, Santosh, Praveen Neeli, K. Sasikumar, et al.. (2018). Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(4). 1115–1128. 117 indexed citations
20.
Gollavilli, Paradesi Naidu, et al.. (2015). AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. FEBS Journal. 282(20). 3971–3985. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026